Jacobs Levy Equity Management
ABOS icon

Jacobs Levy Equity Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,011
Closed -$30.7K – 935
2026
Q1 		$30.7K Buy
+13,011
New +$33.2K ﹤0.01% 952
2025
Q4 		– Sell
-16,001
Closed -$27.4K – 918
2025
Q3 		$27.4K Buy
+16,001
New +$22.1K ﹤0.01% 953

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Jacobs Levy Equity Management's ABOS Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 13,011 shares — an estimated $30.7K sold.

Jacobs Levy Equity Management first reported a position in ABOS in Q3 2025 and held it in 2 quarters. The position peaked at $30.7K in Q1 2026. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 13,011 Acumen Pharmaceuticals shares in Q2 2026, an estimated $30.7K.
  • Jacobs Levy Equity Management first reported a position in Acumen Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Acumen Pharmaceuticals position peaked at $30.7K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.